Jazz Pharma SVP Carr sells 1,287 shares

Jazz Pharmaceuticals SVP and Chief Accounting Officer Patricia Carr reported two share dispositions.

Accepted by SEC EDGAR 03/09/2026 - 05:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Jazz Pharmaceuticals SVP and Chief Accounting Officer Patricia Carr reported two share dispositions. On March 9, 2026, she completed an open-market sale of 1,287 ordinary shares at a weighted average price of $182.94, leaving 6,512 shares directly owned afterward.

On March 5, 2026, she disposed of 1,436 ordinary shares at $186.7723 per share to satisfy tax obligations arising from the vesting of previously granted restricted stock units, resulting in 7,799 shares directly owned following that transaction.

Insider Trade Summary

Net Seller: 1,287 shares

Net Sell 2 txns

Insider Carr Patricia

Role SVP, Chief Accounting Officer

Sold 1,287 shs ($235K)

Share of Position Sold 16.5%

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,287	$182.94	$235K
Exercise Price or Tax Liability	Ordinary Shares	1,436	$186.7723	$268K

Holdings After Transaction: Ordinary Shares — 6,512 shares (Direct)

Holdings Before and After: Ordinary Shares, 9,235 to 6,512 shares (Direct)

Other Insiders: 4 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
2. F2. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $186.06 to $186.9115. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Patricia Carr report in Jazz Pharmaceuticals (JAZZ) Form 4?

Patricia Carr reported two dispositions of Jazz Pharmaceuticals ordinary shares. She sold 1,287 shares in an open-market transaction on March 9, 2026, and disposed of 1,436 shares on March 5, 2026, to cover tax obligations from vesting restricted stock units.

How many Jazz Pharmaceuticals (JAZZ) shares did Patricia Carr sell and at what prices?

Patricia Carr sold 1,287 ordinary shares of Jazz Pharmaceuticals at a weighted average price of $182.94. She also disposed of 1,436 shares at $186.7723 per share in a separate transaction related to tax withholding from vesting restricted stock units.

What was the purpose of Patricia Carr’s March 5, 2026 Jazz (JAZZ) share disposition?

The March 5, 2026 disposition of 1,436 Jazz Pharmaceuticals ordinary shares by Patricia Carr was to satisfy tax obligations. Those obligations arose from the vesting of previously granted restricted stock units, and the shares were delivered as payment rather than sold in an open-market trade.

How many Jazz Pharmaceuticals (JAZZ) shares does Patricia Carr hold after these transactions?

After the March 5, 2026 tax-related disposition, Patricia Carr directly held 7,799 Jazz Pharmaceuticals ordinary shares. Following the March 9, 2026 open-market sale, her direct holdings decreased to 6,512 ordinary shares, as reported in the Form 4 ownership table.

Were Patricia Carr’s Jazz (JAZZ) share sales executed in multiple transactions?

Yes. The filing notes that the ordinary share sales were executed in multiple transactions at prices between $186.06 and $186.9115. The reported price of $182.94 represents a weighted average, and full trade details are available on request from regulators, the issuer, or its security holders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carr Patricia

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/05/2026		F(1)		1,436	D	$186.7723(2)	7,799	D
Ordinary Shares	03/09/2026		S		1,287	D	$182.94	6,512	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

2. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $186.06 to $186.9115. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

	By: /s/Paz Dizon, as attorney in fact For: Patricia Carr	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.